Redmile Group Sells 196,000 ADC Therapeutics Shares, Raising $75 Million in a Strategic Portfolio Shift
Redmile Group’s $75 million ADC Therapeutics sell‑off signals a confidence shift, reshaping investor outlook and offering a discounted entry amid pipeline uncertainty.
4 minutes to read